High weekly doses of liposomal amphotericin B as secondary prophylaxis after cerebral aspergillosis in a paediatric patient

Gallien, 2008, Therapeutic outcome and prognostic factors of invasive aspergillosis in an infectious disease department: a review of 34 cases, Infection, 36, 533, 10.1007/s15010-008-7375-x McCormick, 2010, Aspergillus fumigatus: contours of an opportunistic human pathogen, Cell Microbiol, 12, 1535, 10.1111/j.1462-5822.2010.01517.x Cahuayme-Zuniga, 2012, Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies, Med Mycol: Off Publ Int Soc Hum Anim Mycol, 50, 543, 10.3109/13693786.2011.631152 Walsh, 2007, Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial, Clin Infect Dis, 44, 2, 10.1086/508774 Walsh, 2002, Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children, Pediatr Infect Dis J, 21, 240, 10.1097/00006454-200203000-00015 Gubler, 2007, Disseminated invasive aspergillosis with cerebral involvement successfully treated with caspofungin and voriconazole, Infection, 35, 364, 10.1007/s15010-007-6165-1 Krivan, 2006, Successful combined antifungal salvage therapy with liposomal amphothericin B and caspofungin for invasive Aspergillus flavus infection in a child following allogeneic bone marrow transplantation, Acta Biomed: Atenei Parm, 77, 17 Maertens, 2004, Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy, Clin Infect Dis, 39, 1563, 10.1086/423381 Walsh, 2008, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America, Clin Infect Dis, 46, 327, 10.1086/525258 Karthaus, 2011, Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin – review of the literature, Eur J Med Res, 16, 145, 10.1186/2047-783X-16-4-145 Mele, 2001, Case reports. Secondary prophylaxis with liposomal amphotericin B after invasive aspergillosis following treatment for haematological malignancy, Mycoses, 44, 201, 10.1046/j.1439-0507.2001.00644.x Flohr, 2008, Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia, Leukemia, 22, 771, 10.1038/leu.2008.5 Eschenauer, 2007, Comparison of echinocandin antifungals, Ther Clin Risk Manag, 3, 71, 10.2147/tcrm.2007.3.1.71 Ng, 2000, Successful treatment of Aspergillus brain abscess in a child with acute lymphoblastic leukemia, Pediatr Hematol Oncol, 17, 497, 10.1080/08880010050120863 Pradhan, 2007, Invasive aspergillosis of the brain: improvement with lyposomal amphotericin B and itraconazole, Neurol India, 55, 309, 10.4103/0028-3886.35697 Prakash, 2012, Cerebral Aspergillus infection in pediatric acute lymphoblastic leukemia induction therapy, Indian J Med Paediatr Oncol: Off J Indian Soc Med Paediatr Oncol, 33, 236, 10.4103/0971-5851.107104 Groll, 2000, Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system, J Infect Dis, 182, 274, 10.1086/315643 Kethireddy, 2007, CNS pharmacokinetics of antifungal agents, Expert Opin Drug Metab Toxicol, 3, 573, 10.1517/17425255.3.4.573 Gubbins, 2009, Antimicrob Agents Chemother, 53, 3664, 10.1128/AAC.01448-08